Combined effect of atovaquone and pyrrolidine dithiocarbamate in the treatment of acute murine toxoplasmosis.
Djurković-Djaković
O
O
Toxoplasmosis Research Laboratory, Institute for Medical Research, Belgrade, Serbia and Montenegro. olgicadj@imi.bg.ac.yu
Nikolić
A
A
Bobić
B
B
Klun
I
I
D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D053626:Atovaquone; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D051379:Mice; D009285:Naphthoquinones / Q000008:administration & dosage / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000008:administration & dosage / Q000627:therapeutic use*; D015996:Survival Rate; D013859:Thiocarbamates / Q000008:administration & dosage / Q000627:therapeutic use*; D014124:Toxoplasmosis, Animal / Q000188:drug therapy* / Q000401:mortality
D000975:Antioxidants; D000981:Antiprotozoal Agents; D009285:Naphthoquinones; D011759:Pyrrolidines; D013859:Thiocarbamates; C020972:pyrrolidine dithiocarbamic acid; D053626:Atovaquone